Selective HDAC6 inhibitors (T-518, Tubastatin A, ACY-1215) simultaneously increase α-tubulin acetylation to restore microtubule stability disrupted by tau pathology, reduce tau hyperphosphorylation through improved vesicular transport, and enhance autophagic clearance of aggregated tau. The selectivity of HDAC6 over other HDACs avoids broad transcriptional dysregulation.
Selective HDAC6 inhibition offers the most feasible therapeutic approach among the seven hypotheses, with favorable druggability characteristics including available crystal structures, viable selective inhibitors (ACY-1215/Ricolinostat, Tubastatin A), and demonstrated tolerability in Phase I/II oncology trials. HDAC6's cytoplasmic localization avoids the nuclear toxicity concerns of pan-HDAC inhibition, and its role in regulating microtubule stability and Hsp90 function provides multiple benefic
Verdict Summary
0/10
dimensions won
HDAC6 Inhibition for Dual Restoration of
10/10
dimensions won
HDAC6 Selective Inhibition to Restore Ac
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.58
0.72
Evidence
0.52
0.68
Novelty
0.42
0.55
Feasibility
0.48
0.75
Impact
0.65
0.70
Druggability
0.62
0.82
Safety
0.45
0.65
Competition
0.55
0.70
Data
0.60
0.72
Reproducible
0.48
0.78
Score Breakdown
Dimension
HDAC6 Inhibition for Dual Rest
HDAC6 Selective Inhibition to
Mechanistic
0.580
0.720
Evidence
0.520
0.680
Novelty
0.420
0.550
Feasibility
0.480
0.750
Impact
0.650
0.700
Druggability
0.620
0.820
Safety
0.450
0.650
Competition
0.550
0.700
Data
0.600
0.720
Reproducible
0.480
0.780
Evidence
HDAC6 Inhibition for Dual Restoration of Microtubule Stabili
No evidence citations yet
HDAC6 Selective Inhibition to Restore Acetylation Balance an
No evidence citations yet
Debate Excerpts
HDAC6 Inhibition for Dual Restoration of Microtubu
4 rounds · quality: 0.65
Theorist
# Novel Therapeutic Hypotheses: Disease-Specific Tau PTM Targets
## Hypothesis 1: P300/CBP Acetyltransferase Inhibition to Block K280 Acetylation While Preserving Physiological Acetylation
**Targe...
Skeptic
# Critical Evaluation of Disease-Specific Tau PTM Therapeutic Hypotheses
## Hypothesis 1: P300/CBP Acetyltransferase Inhibition
### Specific Weaknesses in the Evidence
**Enzymatic Specificity Gap...
Domain Expert
# Domain Expert Evaluation: Disease-Specific Tau PTM Drug Targets
## Executive Summary
Of the seven hypotheses, **none currently meet all criteria for an optimal therapeutic target**: disease-spec...